The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $110.68

Today's change-1.30 -1.16%
Updated January 16 1:30 PM -5GMT. Delayed by at least 15 minutes.
 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $110.68

Today's change-1.30 -1.16%
Updated January 16 1:30 PM -5GMT. Delayed by at least 15 minutes.

Reversal following new 50-day high

Ishares Nasdaq Biotechnology is lower today, dropping (U.S.)$1.30 or 1.16% to (U.S.)$110.68 after setting a new 50-day high. Over the last five days, shares are unchanged, but currently 3.05% below the 52-week high. This security has underperformed the S&P 500 by 4.08% during the last year.

Key company metrics

  • Open(U.S.) $112.31
  • Previous close(U.S.) $111.98
  • High(U.S.) $113.30
  • Low(U.S.) $110.63
  • Bid / Ask(U.S.) $110.65 / (U.S.) $110.68
  • YTD % change+3.66%
  • Volume1,741,991
  • Average volume (10-day)2,682,265
  • Average volume (1-month)2,334,817
  • Average volume (3-month)2,644,122
  • 52-week range(U.S.) $88.96 to (U.S.) $114.17
  • Beta1.38
  • Trailing P/E3.66×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.35
  • Dividend yield0.32%
  • Trailing EPS(U.S.) $30.28
Updated January 16 1:30 PM -5GMT. Delayed by at least 15 minutes.
S&P TSX0.26%Sector:FinancialsIndustry:Investment Trusts
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q2/2015Q4/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Sep 30, 201409/30/2014Mar 31, 201403/31/2014Sep 30, 201309/30/2013
Revenue92198
Total other revenue--------
Total revenue92198
Gross profit--------
Total cost of revenue--------
Total operating expense1612118
Selling / general / administrative1612118
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-79-20
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax1,572718446878
Income after tax1,572718446878
Income tax, total0000
Net income1,572718446878
Total adjustments to net income--------
Net income before extra. items1,572718446878
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,572718446878
Inc. avail. to common incl. extra. items1,572718446878
Diluted net income1,572718446878
Dilution adjustment----0--
Diluted weighted average shares86607058
Diluted EPS excluding extraordinary itemsvalue per share18.2612.026.3415.21
Dividends per sharevalue per share0.000.150.000.02
Diluted normalized EPSvalue per share18.2612.026.3415.21